title: Fatigue in multiple sclerosis - a brief review.
abstract: Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions. It can affect a patient's mood, sleep and have a detrimental effect on their quality of life. In the recent years much literature has emerged in an attempt to elucidate the potential causes and treatment of this common symptom. This review article aims to examine the most recent theories on the pathophysiology of fatigue in MS as well as its association with sleep and depression. We describe the pharmacological and non-pharmacological approaches to its treatment and propose a multidisciplinary, patient enabled and individualised manner to the management of fatigue in MS.
authors.affiliation: Division of Clinical Neurology, University of Nottingham, United Kingdom.
authors.forename: Isuru
authors.initials: I
authors.lastname: Induruwa
authors.forename: Cris S
authors.initials: CS
authors.lastname: Constantinescu
authors.forename: Bruno
authors.initials: B
authors.lastname: Gran
mesh_terms: D000547:Amantadine / Q000627:therapeutic use; D001284:Atrophy; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D001921:Brain / Q000473:pathology / Q000503:physiopathology; D002986:Clinical Trials as Topic; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D016207:Cytokines / Q000502:physiology; D003863:Depression / Q000209:etiology / Q000503:physiopathology; D020833:Diffuse Axonal Injury / Q000209:etiology / Q000473:pathology; D004311:Double-Blind Method; D005081:Exercise Therapy; D005221:Fatigue / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control / Q000523:psychology / Q000628:therapy; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D007155:Immunologic Factors / Q000627:therapeutic use; D000077408:Modafinil; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D010389:Pemoline / Q000627:therapeutic use; D010913:Pituitary-Adrenal System / Q000503:physiopathology; D011788:Quality of Life; D016037:Single-Blind Method; D020919:Sleep Disorders, Intrinsic / Q000209:etiology / Q000503:physiopathology
chemical_list: D001559:Benzhydryl Compounds; D016207:Cytokines; D007155:Immunologic Factors; D010389:Pemoline; D000547:Amantadine; D000077408:Modafinil